PG4 Multivalent Vaccine for Pneumococcal Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to provide safety data and demonstrate lot consistency with the PG4 vaccine by evaluating the immunogenicity of 3 different lots of this vaccine.
This study will compare a new pneumococcal vaccine with the vaccine currently in use to see if they are similarly safe. It will also compare three batches of the new vaccine to make sure they work the same way. Blood samples will be taken to measure how the body responds to the vaccines.
The study will be conducted in the United States. Participants will be assigned to 1 of 4 groups. Group 1: PG4 vaccine lot 1; Group 2: PG4 vaccine lot 2; Group 3: PG4 vaccine lot 3; Group 4: 20vPnC.
Within each group, participants will be assigned by chance in a 2:2:2:1 ratio to receive 1 vaccine injection (shot) with either PG4 (new vaccine) lot 1, PG4 lot 2, PG4 Lot 3 or 20vPnC, given in the arm. This means that for every 7 participants, about 2 will receive either PG4 lot 1, lot 2 or lot 3 and about 1 will receive 20vPnC.
Each participant will take part in the study for approximately 6 months.
Who Is on the Research Team?
Pfizer CT.gov Call Center
Principal Investigator
Pfizer
Are You a Good Fit for This Trial?
This trial is for adults in the United States who are generally healthy and able to receive a pneumococcal vaccine. People with certain health conditions or allergies that could interfere with vaccination may not be eligible.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- 20 Valent Pneumococcal Conjugate Vaccine (20vPnC)
- PG4 Multivalent Vaccine
Trial Overview
The study compares three different batches of a new multivalent pneumococcal vaccine (PG4) to each other and to an existing approved vaccine (20vPnC). Participants get one shot, assigned by chance, and their immune response is measured over about 6 months.
How Is the Trial Designed?
4
Treatment groups
Experimental Treatment
Active Control
Multivalent Pneumococcal Vaccine
Multivalent Pneumococcal Vaccine
Multivalent Pneumococcal Vaccine
20 Valent Pneumococcal Conjugate Vaccine
Find a Clinic Near You
Who Is Running the Clinical Trial?
Pfizer
Lead Sponsor
Albert Bourla
Pfizer
Chief Executive Officer since 2019
PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki
Patrizia Cavazzoni
Pfizer
Chief Medical Officer
MD from McGill University
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.